单核吞噬细胞系统
体内分布
核糖核酸
体内
信使核糖核酸
全身给药
细胞生物学
生物
纳米技术
化学
免疫学
材料科学
生物化学
基因
生物技术
作者
Roy Pattipeiluhu,Gabriela Arias‐Alpizar,Genc Basha,Karen Y. T. Chan,Jeroen Bussmann,Thomas H. Sharp,Mohammad‐Amin Moradi,Nico A. J. M. Sommerdijk,Edward N. Harris,Pieter R. Cullis,Alexander Kros,Dominik Witzigmann,Frederick Campbell
标识
DOI:10.1002/adma.202201095
摘要
Lipid nanoparticles (LNPs) are the leading nonviral technologies for the delivery of exogenous RNA to target cells in vivo. As systemic delivery platforms, these technologies are exemplified by Onpattro, an approved LNP-based RNA interference therapy, administered intravenously and targeted to parenchymal liver cells. The discovery of systemically administered LNP technologies capable of preferential RNA delivery beyond hepatocytes has, however, proven more challenging. Here, preceded by comprehensive mechanistic understanding of in vivo nanoparticle biodistribution and bodily clearance, an LNP-based messenger RNA (mRNA) delivery platform is rationally designed to preferentially target the hepatic reticuloendothelial system (RES). Evaluated in embryonic zebrafish, validated in mice, and directly compared to LNP-mRNA systems based on the lipid composition of Onpattro, RES-targeted LNPs significantly enhance mRNA expression both globally within the liver and specifically within hepatic RES cell types. Hepatic RES targeting requires just a single lipid change within the formulation of Onpattro to switch LNP surface charge from neutral to anionic. This technology not only provides new opportunities to treat liver-specific and systemic diseases in which RES cell types play a key role but, more importantly, exemplifies that rational design of advanced RNA therapies must be preceded by a robust understanding of the dominant nano-biointeractions involved.
科研通智能强力驱动
Strongly Powered by AbleSci AI